公开(公告)号：US11781115B2

公开(公告)日：2023-10-10

申请号：US16782579

申请日：2020-02-05

Applicant: TOPPAN PRINTING CO., LTD. ,  Japanese Foundation For Cancer Research

Inventor： Yuki Takahashi ,  Shiro Kitano ,  Ryohei Katayama ,  Satoshi Nagayama

IPC: C12N5/09

CPC classification number: C12N5/0693 ,  C12N2502/11 ,  C12N2502/1323 ,  C12N2502/28 ,  C12N2509/10 ,  C12N2513/00 ,  C12N2533/30 ,  C12N2533/90

Abstract: A primary culture method in which cells contained in a tissue collected from a living body are primary cultured in vitro, in which the cells in the tissue collected from the living body are seeded and cultured on a top surface of a cell structure containing cells constituting a stroma and composed of a single layer or two or more cell layers laminated in the thickness direction.

公开(公告)号：US20230255467A1

公开(公告)日：2023-08-17

申请号：US17997028

申请日：2021-04-15

Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH ,  AI Medical Service Inc.

Inventor： Yohei IKENOYAMA ,  Sho SHIROMA ,  Toshiyuki YOSHIO ,  Tomohiro TADA

IPC: A61B1/273 ,  G06T7/00 ,  G16H50/20 ,  A61B1/00

CPC classification number: A61B1/273 ,  G06T7/0012 ,  G16H50/20 ,  A61B1/00045 ,  G06T2207/10016 ,  G06T2207/10068 ,  G06T2207/20081 ,  G06T2207/30096

Abstract: Provided are a diagnostic imaging device, a diagnostic imaging method, a diagnostic imaging program and a learned model, which can improve the diagnostic accuracy for esophagus cancer in esophagogastroduodenoscopy. This diagnostic imaging device comprises: an endoscopic image acquisition unit for acquiring an endoscopic moving image showing the esophagus of a person being tested; an estimation unit for estimating the location of esophagus cancer that is present in the acquired endoscopic moving image, using a convolutional neural network that has learned from esophagus cancer images as training data, the esophagus cancer images having been obtained from esophaguses affected by esophagus cancer; and a display control unit that superimposes on the endoscopic moving image an estimated location of the esophagus cancer and a certainty factor serving as an index for the probability that esophagus cancer is present at that location.

公开(公告)号：US20230121965A1

公开(公告)日：2023-04-20

申请号：US18069509

申请日：2022-12-21

Applicant: TOPPAN INC. ,  Japanese Foundation For Cancer Research

Inventor： Shiro KITANO ,  Eiji SHINOZAKI

IPC: G06N3/09

Abstract: An evaluation device for evaluating an anticancer effect includes a learning information acquisition unit that acquires learning data that includes state information which indicates at least a cancer state in an unspecified subject and training data that is information about an effect of an anticancer agent obtained by administering the anticancer agent to cells collected from the subject, a learning unit that generates a prediction model by causing a learning model to perform supervised learning for a corresponding relationship between the learning data and the training data, and a prediction unit that makes related predictions to therapy using the anticancer agent with the prediction model. The learning information acquisition unit acquires the information about the anticancer effect obtained by administering the anticancer agent to a three-dimensional cell structure including cancer cells collected from the unspecified subject and cells constituting a stroma as the training data.

公开(公告)号：US11530266B2

公开(公告)日：2022-12-20

申请号：US16626162

申请日：2019-06-14

Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH ,  API CO., LTD.

Inventor： Nobuhiko Gyobu ,  Naoya Fujita ,  Mamoru Kakino ,  Ai Kawashima ,  Shinya Fujihara ,  Naoki Goda

IPC: C07K16/28 ,  C07K16/46 ,  A61K39/00

Abstract: The object of the present invention is to provide a humanized or mouse-human chimeric anti-podoplanin antibody or an antibody fragment containing the antigen-binding region thereof, and the object is achieved by providing an isolated humanized or mouse-human chimeric anti-podoplanin antibody which comprises a predetermined amino acid sequence, or an antibody fragment containing the antigen-binding region thereof.

公开(公告)号：US20210140943A1

公开(公告)日：2021-05-13

申请号：US17144776

申请日：2021-01-08

Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH

Inventor： Kengo Takeuchi ,  Seiji Sakata ,  Yuki Togashi ,  Naoya Fujita ,  Ryohei Katayama

IPC: G01N33/50 ,  C12N9/12 ,  G01N33/574 ,  C12N9/88 ,  C07K14/82 ,  A61K31/519 ,  A61P35/00 ,  A61K38/00 ,  C12N15/113 ,  C12N15/62

Abstract: It is intended to reveal a polynucleotide serving as a novel causative gene of a cancer and, on the basis of this finding, to provide a method for detecting the polynucleotide or a polypeptide encoded thereby, a kit and a primer set for the detection, a method for screening for a substance that inhibits the polypeptide, and a pharmaceutical composition for the treatment of a cancer, containing the inhibiting substance. The detection method of the present invention detects a BRAF fusion protein or a fusion gene encoding the fusion protein, or a PXN or GMDS fusion protein or a fusion gene encoding the fusion protein in a digestive organ-derived sample obtained from a subject.

公开(公告)号：US20210061789A1

公开(公告)日：2021-03-04

申请号：US16958066

申请日：2018-12-26

Applicant: RIKEN ,  JAPANESE FOUNDATION FOR CANCER RESEARCH ,  KABUSHIKI KAISHA YAKULT HONSHA

Inventor： Minoru YOSHIDA ,  Hiroyuki SEIMIYA ,  Yoko YASHIRODA ,  Kenichi WASHIZUKA ,  Fumiyuki SHIRAI ,  Nobuko YOSHIMOTO ,  Junichi KAZAMI

IPC: C07D403/04 ,  C07D498/06

Abstract: Provided is a cell proliferation inhibitor comprising a compound of the formula (1) or a pharmacologically acceptable salt thereof: wherein J1 and J2 each represent CH or N, with the proviso that J1 and J2 are not simultaneously CH; r represents 0 to 4; each R101 is the same or different when r is 2 or more, and R101 represents a C1-6 alkyl group optionally substituted with a halogen atom or the like; s represents 0 to 5; each R102 is the same or different when s is 2 or more, and R102 represents a halogen atom or the like; R103 represents a hydrogen atom, a C1-6 alkyl group, a C3-6 cycloalkyl group, or a C3-6 cycloalkyl C1-6 alkyl group; and R101 and R103 are optionally linked together to form a five- to seven-membered ring hetero ring when R101 is present at the 8-position.

公开(公告)号：US10705087B2

公开(公告)日：2020-07-07

申请号：US14907689

申请日：2014-07-25

Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH

Inventor： Kengo Takeuchi ,  Yuki Togashi ,  Seiji Sakata ,  Satoko Baba

IPC: C12Q1/68 ,  G01N33/574 ,  C12Q1/6886 ,  G01N33/50 ,  A61K31/277 ,  A61K31/553

Abstract: A polynucleotide, which is a novel causative gene for cancer, is elucidated, and, based on this finding, provided are a method for detecting the polynucleotide, or a polypeptide encoded by the polynucleotide; a kit and a primer set for the detection; a method for screening an inhibitor of the polypeptide; and a pharmaceutical composition for treating a cancer containing the inhibitor. In the detection method of the present invention, an NTRK3 fusion protein, or a fusion gene encoding the fusion protein, or an ETV6 fusion protein, or a fusion gene encoding the fusion protein, in a sample derived from the digestive system obtained from a subject, is detected.

公开(公告)号：US20200172554A1

公开(公告)日：2020-06-04

申请号：US16314101

申请日：2017-06-30

Applicant: RIKEN ,  JAPANESE FOUNDATION FOR CANCER RESEARCH

Inventor： Minoru YOSHIDA ,  Hiroyuki SEIMIYA ,  Masayuki OKUE ,  Yoko YASHIRODA ,  Fumiyuki SHIRAI ,  Takeshi TSUMURA ,  Yuko KANO ,  Kenichi WASHIZUKA ,  Nobuko YOSHIMOTO ,  Yasuko KOUDA ,  Takehiro FUKAMI ,  Tsubasa CHIKADA ,  Takashi WATANABE

IPC: C07D519/00 ,  C07D471/10 ,  C07D471/20 ,  C07D491/107

Abstract: Provided are 2-(piperidin-1-yl)pyrimidin-4(3H)-ones or pharmaceutically acceptable salts thereof, each characterized by having a 1,8-diazaspiro[4.5]deca-3-ene, 1-oxa-8-azaspiro[4.5]deca-3-ene, 2,8-diazaspiro[4.5]deca-3-ene, 2-oxa-8-azaspiro[4.5]deca-3-ene, 2,9-diazaspiro[5.5]undeca-3-ene, 1-oxa-9-azaspiro[5.5]undeca-3-ene, 1,9-diazaspiro[5.5]undeca-4-ene, or 3,9-diazaspiro[5.5]undeca-1-ene structure represented by the following general formula (1):

公开(公告)号：US10585100B2

公开(公告)日：2020-03-10

申请号：US15569898

申请日：2016-04-28

Applicant: KYOTO UNIVERSITY ,  JAPANESE FOUNDATION FOR CANCER RESEARCH

Inventor： Seishi Ogawa ,  Keisuke Kataoka ,  Kengo Takeuchi

IPC: G01N33/574 ,  A61K39/395 ,  C12Q1/68 ,  C12N15/09 ,  A61K45/00 ,  C07K16/28 ,  C07K16/18

Abstract: An object of the present invention is to provide an effective method of predicting an effect of treatment by a PD-1/PD-L1 blockade, which is a method of predicting whether or not PD-1/PD-L1 blockade is effective for treatment of a subject suffering from a malignant tumor, which comprises detecting abnormality of genome relating to effectiveness of the PD-1/PD-L1 blockade in a tumor cell taken from the subject and evaluating the PD-1/PD-L1 blockade as useful for the treatment of the subject when there is the abnormality.

公开(公告)号：US20190310258A1

公开(公告)日：2019-10-10

申请号：US16345539

申请日：2017-10-26

Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH ,  OSAKA UNIVERSITY

Inventor： Koji Ueda ,  Naomi Ohnishi ,  Norio Nonomura ,  Motohide Uemura ,  Kazutoshi Fujita ,  Kazutake Tsujikawa ,  Kentarou Jingushi

IPC: G01N33/574 ,  C12Q1/6886

Abstract: Provided is a method wherein an affected tissue and a normal tissue obtained from the vicinity of the affected tissue are left at rest in a culture medium, and a disease-specific biomarker is searched for in an exudate therefrom. A biomarker specific to renal cell carcinoma has been found by this method.